China NMPA's Center for Drug Evaluation (CDE) has granted priority review for InnoCare Pharma's zurletrectinib (ICP-723) ...

TAE Life Sciences (TLS) has signed a letter of intent with the OSUCCC – James to develop boron-based drug compounds for ...

The US FDA has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg oral formulation of Wegovy ...

The US HHS has launched a $500m initiative to accelerate the development of universal vaccines targeting viruses with ...

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

The London Cancer Hub has been identified as a key district for ‘frontier innovation’ by London Mayor Sadiq Khan.

The FDA has granted approval for AbbVie’s 15mg Rinvoq (upadacitinib) to treat adults with giant cell arteritis (GCA).

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

As scientists explore treating genetic disorders before birth, the promise of foetal gene therapy is growing—but there are ...

D Molecular Therapeutics (4DMT) has received the regenerative medicine advanced therapy (RMAT) designation from the FDA for ...

The expiration of the FDA’s paediatric priority review voucher programme is creating uncertainty for rare disease drug ...

Whilst 2025 outlooks include cost impact from existing tariffs, companies have not adjusted their guidance for future ...